The CytoVive® Standard
At CytoVive® we believe that all humans and animals deserve access to next generation treatments, and our mission is to bring healthcare professionals, veterinarians, and scientific researchers that next generation of functional medicine solutions.
All CytoVive® Medical Devices, Allograft Aliquots, and Research Chemicals go through an extensive vetting process for the following criteria:
​
1. Devices must have no adverse events and only minimal (if any) side effects reported with use.
2. Devices must possess proprietary qualities that revolutionize their respective application(s).
3. Devices must be FDA registered and regulated -
A) Under 21 CFR Part 1271 & PHS Act Section 361; or
B) As a Class 2 510(k) approved device under 21 CFR Part 807.92 (a) (3).
C) As a 505(b)(2) NDA Pharmaceutical under the Federal Food, Drug, and Cosmetic Act.
D) Under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019.
4. Allograft Tissue Aliquots - must be certified by an independent third party laboratory (registered as a 501(c)(3)) for product sterility and viability.
​
